曲美他嗪对冠心病稳定性劳力型心绞痛患者心肌缺血的影响  

Effect of Trimetazidine on myocardial ischemia in patients with coronary heart disease complicated with stable exertional angina pectoris

作　　者：陈连娣 

机构地区：[1]辽宁省开原市中医医院综合内科,辽宁开原112300

出　　处：《中国当代医药》2017年第1期62-64,共3页China Modern Medicine

摘　　要：目的探讨曲美他嗪对冠心病稳定性劳力型心绞痛患者心肌缺血的影响。方法选取本院2014年5月~2016年4月收治的90例冠心病稳定性劳力型心绞痛患者为研究对象,利用计算机进行随机分组,将患者分成两组,每组45例。对照组实施常规药物治疗,在常规药物治疗的基础上观察组给予曲美他嗪治疗。比较两组患者的运动试验结果、1周内心绞痛发作次数、心率以及心率和收缩压乘积、治疗效果。结果观察组患者治疗后的运动试验结果:ST段达1 mm时间[(405.39±52.16)s]、运动诱发心绞痛发作时间[(453.26±59.24)s],运动持续时间[(681.26±53.46)s]均长于对照组[(314.26±52.16)s、(351.34±50.31)s、(505.34±41.36)s](P<0.05)。观察组的1周内心绞痛发作次数[(1.34±0.28)次]明显少于对照组[(4.56±1.25)次](P<0.05),两组患者的心率、心率和收缩压乘积差异无统计学意义(P>0.05)。观察组的治疗总有效率(95.56%)高于对照组(68.89%)(P<0.05)。结论曲美他嗪是治疗冠心病稳定性劳力型心绞痛的有效药物,能有效预防或改善患者的心肌缺血症状。Objective To explore the effect of Trimetazidine on myocardial ischemia in patients with coronary heart disease（CHD） complicated with stable exertional angina pectoris.Methods 90 patients with CHD complicated with stable exertional angina pectoris treated by our hospital from May 2014 to April 2016 were selected as research objects.They were evenly divided into two groups by computer randomization with 45 cases in each group.In control group,conventional drug therapy was used,while in research group,on the basis of the conventional drug therapy,Trimetazidine was added.The motion testing outcome,frequency of angina pectoris attack in one week,heart rate,heart rate-systolic blood pressure product,and therapeutic effect were compared between two groups.Results The motion testing outcome of the observa tion group：ST segment lasting 1 mm [（405.39±52.16） s],attack time of exercise-induced angina pectoris [（453.26±59.24） s],the exercise-lasting time [（681.26±53.46） s] was longer than those of control group [（314.26±52.16） s,（351.34±50.31） s,（505.34±41.36） s]（P〈0.05）.The frequency of angina pectoris attack in one week [（1.34 ±0.28） times] in the observation group was obviously fewer than that of control group [（4.56±1.25） times]（P〈0.05）.There was no statistical difference in heart rate and heart rate-systolic blood pressure product between two groups（P〉0.05）.The total effective rate（95.56%）in observation group was higher than that of the control group（68.89%）（P〈0.05）.Conclusion Trimetazidine is an effective drug in the treatment of CHD complicated with stable exertional angina pectoris,and can effectively prevent or improve the symptoms of myocardial ischemia in patients.

关 键 词：曲美他嗪 稳定性劳力型心绞痛 心肌缺血 

分 类 号：R541.4[医药卫生—心血管疾病]